TY - JOUR
T1 - Do presenting symptoms, use of pre-diagnostic endoscopy and risk of emergency cancer diagnosis vary by comorbidity burden and type in patients with colorectal cancer?
AU - Majano, Sara Benitez
AU - Lyratzopoulos, Georgios
AU - Rachet, Bernard
AU - de Wit, Niek J.
AU - Renzi, Cristina
N1 - Funding Information:
This paper arises from the CanTest Collaborative, which is funded by Cancer Research UK (C8640/A23385), of which GL is Associate Director and CR Faculty member, and it is additionally supported by the International Alliance for Cancer Early Detection, a partnership between Cancer Research UK [C18081/A31373], Canary Center at Stanford University, the University of Cambridge, OHSU Knight Cancer Institute, University College London and the University of Manchester. SBM and BR acknowledge funding from the Prevention and Population Research Committee - Programme Award (C7923/A29018). GL is supported by a Cancer Research UK Clinician Advanced Scientist Fellowship (grant number C18081/A18180). NdW acknowledges funding from the Dutch Cancer Society (number 50-56300-98-587). CR acknowledges funding from Cancer Research UK - Early Detection and Diagnosis Committee (grant number EDDCPJT\100018).
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/3
Y1 - 2022/3
N2 - Background: Cancer patients often have pre-existing comorbidities, which can influence timeliness of cancer diagnosis. We examined symptoms, investigations and emergency presentation (EP) risk among colorectal cancer (CRC) patients by comorbidity status. Methods: Using linked cancer registration, primary care and hospital records of 4836 CRC patients (2011–2015), and multivariate quantile and logistic regression, we examined variations in specialist investigations, diagnostic intervals and EP risk. Results: Among colon cancer patients, 46% had at least one pre-existing hospital-recorded comorbidity, most frequently cardiovascular disease (CVD, 18%). Comorbid versus non-comorbid cancer patients more frequently had records of anaemia (43% vs 38%), less frequently rectal bleeding/change in bowel habit (20% vs 27%), and longer intervals from symptom-to-first relevant test (median 136 vs 74 days). Comorbid patients were less likely investigated with colonoscopy/sigmoidoscopy, independently of symptoms (adjusted OR = 0.7[0.6, 0.9] for Charlson comorbidity score 1–2 and OR = 0.5 [0.4–0.7] for score 3+ versus 0. EP risk increased with comorbidity score 0, 1, 2, 3+: 23%, 35%, 33%, 47%; adjusted OR = 1.8 [1.4, 2.2]; 1.7 [1.3, 2.3]; 3.0 [2.3, 4.0]) and for patients with CVD (adjusted OR = 2.0 [1.5, 2.5]). Conclusions: Comorbid individuals with as-yet-undiagnosed CRC often present with general rather than localising symptoms and are less likely promptly investigated with colonoscopy/sigmoidoscopy. Comorbidity is a risk factor for diagnostic delay and has potential, additionally to symptoms, as risk-stratifier for prioritising patients needing prompt assessment to reduce EP.
AB - Background: Cancer patients often have pre-existing comorbidities, which can influence timeliness of cancer diagnosis. We examined symptoms, investigations and emergency presentation (EP) risk among colorectal cancer (CRC) patients by comorbidity status. Methods: Using linked cancer registration, primary care and hospital records of 4836 CRC patients (2011–2015), and multivariate quantile and logistic regression, we examined variations in specialist investigations, diagnostic intervals and EP risk. Results: Among colon cancer patients, 46% had at least one pre-existing hospital-recorded comorbidity, most frequently cardiovascular disease (CVD, 18%). Comorbid versus non-comorbid cancer patients more frequently had records of anaemia (43% vs 38%), less frequently rectal bleeding/change in bowel habit (20% vs 27%), and longer intervals from symptom-to-first relevant test (median 136 vs 74 days). Comorbid patients were less likely investigated with colonoscopy/sigmoidoscopy, independently of symptoms (adjusted OR = 0.7[0.6, 0.9] for Charlson comorbidity score 1–2 and OR = 0.5 [0.4–0.7] for score 3+ versus 0. EP risk increased with comorbidity score 0, 1, 2, 3+: 23%, 35%, 33%, 47%; adjusted OR = 1.8 [1.4, 2.2]; 1.7 [1.3, 2.3]; 3.0 [2.3, 4.0]) and for patients with CVD (adjusted OR = 2.0 [1.5, 2.5]). Conclusions: Comorbid individuals with as-yet-undiagnosed CRC often present with general rather than localising symptoms and are less likely promptly investigated with colonoscopy/sigmoidoscopy. Comorbidity is a risk factor for diagnostic delay and has potential, additionally to symptoms, as risk-stratifier for prioritising patients needing prompt assessment to reduce EP.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Colonoscopy/methods
KW - Colorectal Neoplasms/diagnosis
KW - Comorbidity
KW - Delayed Diagnosis
KW - Humans
KW - Logistic Models
KW - Middle Aged
KW - Multivariate Analysis
KW - Registries
KW - Sigmoidoscopy
KW - Young Adult
UR - http://www.scopus.com/inward/record.url?scp=85118650081&partnerID=8YFLogxK
U2 - 10.1038/s41416-021-01603-7
DO - 10.1038/s41416-021-01603-7
M3 - Article
C2 - 34741134
AN - SCOPUS:85118650081
SN - 0007-0920
VL - 126
SP - 652
EP - 663
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 4
ER -